MEPACT

Chemicals for use in the manufacture of preparations for medical or veterinary use, particularly muramyl peptides and muramyl tripeptides, muramyl tripeptide phosphatidyl ethanolamine (MTP-PE), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2 (1, 2-dipalmitoyl-sn-g lycero-3-hydroxyphosphoryloxy)-ethylamide, hexopyranose and formulations of muramyl peptides, particularly liposomal formulations, pharmaceutically acceptable forms of muramyl peptides, pharmaceutically acceptable salts of muramyl peptides, all of these products being more specifically meant to be used for anti-cancer therapy, antiviral therapy, neoplasia and pathologies induced by chemotherapy, particularly mucositis, myelosuppression, peripheral neuropathy

Preparations for medical or veterinary use, particularly muramyl peptides and muramyl tripeptides, muramyl tripeptide phosphatidyl ethanolamine (MTP-PE), N-acetylmuramyl-L-alanyl- D-isoglutaminyl-L-alanine-2 (1, 2-dipalmitoyl-sn-qlycero-3-hydroxyphosphoryloxy)-ethylamide, hexopyranose and formulations of muramyl peptides, particularly liposomal formulations, pharmaceutically acceptable forms of muramyl peptides, and pharmaceutically acceptable salts of muramyl peptides, all of these products being more specifically meant to be used for anti-cancer therapy, antiviral therapy, neoplasia and pathologies induced by chemotherapy, particularly mucositis, myelosuppression, peripheral neuropathy; pharmaceutical preparations for anti-cancer and antiviral therapies, neoplasia, and pathologies induced by chemotherapy, particularly mucositis, myelosuppression, peripheral neuropathy